Follicular Lymphoma
News
‘Excellent’ survival with HCT despite early treatment failure in FL
Autologous and allogeneic hematopoietic stem cell transplantation (HCT) both offer excellent long-term survival in follicular lymphoma (FL)...
Conference Coverage
Chemo-free combo provides potential first-line option for FL
CHICAGO—A chemotherapy-free combination of lenalidomide plus rituximab shows similar efficacy and a different safety profile to chemotherapy plus...
Conference Coverage
Polatuzumab plus BR improves efficacy in DLBCL
CHICAGO—Polatuzumab vedotin, when added to bendamustine (B) and rituximab (R), significantly improved response and survival rates in a cohort of...
Conference Coverage
Chemo-free regimen appears viable in previously untreated FL
CHICAGO – Could lenalidomide plus rituximab be a first-line option?
Conference Coverage
Novel antibody shifts ‘eat me/don’t eat me’ balance in refractory NHL
CHICAGO – Treatment with Hu5F9-G4 (5F9) produced “encouraging” antitumor activity in a phase 1b study of 22 patients.
Clinical Review
Aggressive B-Cell Non-Hodgkin Lymphoma
News
Umbralisib has ‘distinct’ safety profile
Phase 1 trial results suggest umbralisib, a PI3Kδ/CK1ε inhibitor, can be safe and active in patients with relapsed or refractory B-cell...
Feature
2017 notches up some landmark approvals
News
Drug granted fast track designations for FL, DLBCL
The US Food and Drug Administration (FDA) has granted 2 fast track designations to 5F9, an anti-CD47 antibody. The designations are for 5F9 as a...
Conference Coverage
Early results favor combo IL-15/anti-CD20 in indolent NHL
CHICAGO – The researchers tested the combination of rituximab with the IL-15 receptor super agonist complex ALT-803.
News
Novartis CAR T-cell therapy adds a lymphoma indication
The new approval puts tisagenlecleucel head to head with Gilead’s axicabtagene ciloleucel.